Brief: Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million
12/11/2019 22:54
Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS REPORTS THIRD QUARTER 2019 RESULTS
* QTRLY LOSS PER SHARE C$0.021
* QTRLY REVENUE C$4 MILLION VERSUS C$ 3.2 MILLION
* Q3 EARNINGS PER SHARE VIEW C$0.03, REVENUE VIEW C$3.4
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nGNX1b1Mzn
Further company coverage: GUD.TO
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil